Quest Laboratories Enters Strategic Growth Agreement with Consortium for Expansion and IPO Readiness
Quest Laboratories Limited has executed a comprehensive Strategic Mandate Agreement with Niraga Capitals Private Limited and an associated consortium of experts. The agreement is designed to facilitate strategic marketing, business development, operational cadence improvements, export-market expansion, and fundraising facilitation services over the next five years.The mandate was signed on July 22, 2026, between Quest Laboratories Limited and the group comprising Niraga Capitals Private Limited, Mr. Athar Ali Nagpurwala, and consortium members including Mr. Rajan Puri, Mr. Sunil B. Bajaj, Mr. Romil Agrawal, and Mr. Manoj Khajanchi. The transaction is confirmed to be on an arm's length basis, and the counterparty does not belong to the Promoter or Promoter Group of Quest Laboratories Limited.
The overarching goal of the engagement is to scale company operations, expand domestic and international institutional markets, strengthen operational infrastructure, facilitate necessary growth capital, and prepare the organization for a transition toward NSE Mainboard listing.
Scope and Phased Approach
The consortium has outlined a structured four-phase plan designed to guide the company through diagnostics, growth planning, market acceleration, and eventual scale execution.Key phases of the agreement include:
- Phase 1 (Months 1–3): Focuses on diagnostics, baseline creation, establishing a data room, defining KPI architecture, and creating a 100-day plan.
- Phase 2 (Months 3–12): Aims to deliver the growth plan, capital plan, investor deck development, and establish an export and institutional strategy.
- Phase 3 (Months 13–36): Centers on revenue acceleration, improving operating cadence, developing export orders, facilitating investor introductions, and executing consistent investor communication.
- Phase 4 (Months 36–60): Focuses on scale execution, strategic partnerships development, market re-rating, and preparing the company for mainboard migration.
Financials and Consideration Structure
The agreement features a complex fee and consideration structure tied to operational performance and future valuation milestones.The terms agreed upon include:
| Type of Compensation | Details |
|---|---|
| EBITDA-Linked Commission | 30% commission on yearly EBITDA growth or excess, structured as 50% in cash and 50% via private placement allotment of equity shares. |
| Valuation-Linked Equity | Issuance of up to an aggregate of 9% equity shares on a fully diluted basis upon achieving market capitalization milestones ranging from 2250 Cr to 21,000 Cr. This milestone period is maintained for 60 to 90 trading days. |
| Success Fee (Fundraising) | Equity Fundraise: 5% of Gross Consideration. Debt/Quasi-Equity: 3% of Gross Consideration. Strategic M&A: Minimum 5% of Gross Consideration. |
The five-year tenure provides the necessary runway for the consortium to guide Quest Laboratories Limited through comprehensive market expansion and institutional readiness.
QUESTLAB Stock Price Movement
On Thursday, shares of Quest Laboratories Limited held steady, settling at ₹95 after recording zero change during the trading session. The stock traded a total quantity of 44,400 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.